[In vitro evaluation of gentamicin and teicoplanin release from cancellous human bone].
OBJECTIVE
This study was designed to determine the in vitro antibacterial activity of gentamicin- or teicoplanin-impregnated human cancellous bone as a local antibiotic carrier.


METHODS
The study samples were obtained from human cancellous bone within the femur head in seven patients who underwent partial or total hip arthroplasty. Bone specimens were processed and incubated with gentamicin or teicoplanin for an hour. Control bone specimens were soaked in sterile saline solution for the same duration. Antibiotic release of bone specimens was assessed by the disc diffusion technique after 1, 3, 7, 10, 14. 18, and 21 days of antibiotic impregnation, with seven samples in each group. The test strains were E. coli ATCC 25922 for gentamicin, and S. aureus ATCC 25923 for teicoplanin. In vitro antibiotic efficacy was defined as an inhibition zone diameter of = or >15 mm for gentamicin, and = or >14 mm for teicoplanin.


RESULTS
Evaluation of inhibition zone diameters showed that bone-teicoplanin complexes had a longer duration of antibiotic release than that of bone-gentamicin complexes (12 to 18 days vs 7 to 10 days). There was no inhibition in the control group. There were no significant differences in inhibition zone diameters of teicoplanin- and gentamicin-treated specimens on the first and third days; however, teicoplanin exhibited significantly greater zone diameters on the seventh (p=0.008) and tenth (p=0.003) days.


CONCLUSIONS
Our data show that, under appropriate conditions, human cancellous bone incorporates a considerable amount of teicoplanin and exhibits effective antibiotic release for approximately two weeks.
Kazimoğlu
Cemal
C
Department of Orthopedics and Traumatology (1. Ortopedi ve Travmatoloji Kliniği), Izmir Atatürk Training and Research Hospital, Izmir, Turkey. ckazimoglu2000@yahoo.com
Karapinar
Hasan
H
Sener
Muhittin
M
Afşar
Ilhan
I
Sener
Asli-Gamze Karataş
AG
Akgün
Ulaş
U
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D004926:Escherichia coli / Q000187:drug effects*; D005270:Femur Head / Q000382:microbiology*; D005839:Gentamicins / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008826:Microbial Sensitivity Tests; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects*; D017334:Teicoplanin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D017334:Teicoplanin